CJC-1295 vs GHRP-2
A neutral, side-by-side comparison of two performance & growth hormone peptides — their mechanisms, dosing ranges, administration routes, side effects, and research evidence. For research and educational purposes only.
CJC-1295
CJC-1295 is a synthetic growth hormone-releasing hormone (GHRH) analog. It stimulates the pituitary gland to release growth hormone and is almost universally used in combination with a GHRP like Ipamorelin to produce a more physiological GH pulse.
Full profileGHRP-2
GHRP-2 is a synthetic hexapeptide that acts as a ghrelin mimetic, stimulating the pituitary gland to secrete growth hormone (GH). It is one of the most potent GH secretagogues studied, producing stronger GH pulses than GHRP-6 with comparatively less appetite stimulation.
Full profile| CJC-1295 | GHRP-2 | |
|---|---|---|
| Category | Performance & Growth Hormone | Performance & Growth Hormone |
| Also known as | CJC-1295 DAC, CJC-1295 without DAC (Mod GRF 1-29), Modified GRF 1-29 | Growth Hormone Releasing Peptide-2, Pralmorelin, KP 102 |
| Evidence | Research-stage | Preclinical only |
| Dosing range | 100mcg–300mcg mcg, once daily (Mod GRF) or twice weekly (DAC version) | 100mcg–300mcg mcg, 1–3 times daily, on an empty stomach |
| Administration | Subcutaneous injection (most common), Intramuscular injection | Subcutaneous injection, Intramuscular injection |
| Key side effects | Water retention (especially early in protocol), Tingling or numbness in extremities, Injection site redness, Flushing (transient, shortly after injection) | Increased hunger (less than GHRP-6), Elevated cortisol and prolactin at high doses, Water retention, Injection site irritation |
| Cited sources | 2 references | 3 references |
Key differences
- Evidence level differs: CJC-1295 is research-stage, while GHRP-2 is preclinical only.
- Administration: CJC-1295 — Subcutaneous injection (most common), Intramuscular injection; GHRP-2 — Subcutaneous injection, Intramuscular injection.
- Frequency: CJC-1295 is typically once daily (Mod GRF) or twice weekly (DAC version); GHRP-2 is 1–3 times daily, on an empty stomach.
- Research depth: this profile cites 2 sources for CJC-1295 vs 3 for GHRP-2.
How each works
CJC-1295
Studies have demonstrated that CJC-1295 significantly increases plasma GH and IGF-1 levels. The DAC (Drug Affinity Complex) version extends the half-life to approximately 6–8 days via albumin binding, while Mod GRF 1-29 has a much shorter half-life (~30 minutes) and is dosed more acutely. Research in adults with GH deficiency has shown improved body composition and metabolic markers.
GHRP-2
GHRP-2 has been extensively studied in both animal and human subjects. Clinical trials have demonstrated significant GH elevation in healthy adults, with a peak GH pulse occurring 15–30 minutes post-injection. Studies show it increases IGF-1 levels with chronic use and may have mild cardioprotective properties. Unlike GHRP-6, it has a lower propensity to stimulate cortisol and prolactin at standard doses.
This comparison aggregates public research and structured profile data for informational purposes only. It is not medical advice and does not recommend either compound for human use. Consult a qualified healthcare provider before considering any peptide.